MCM
ATYR

MAI Capital Management’s aTyr Pharma ATYR Stock Holding History

MAI Capital Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1K Buy
16,846
+3,342
+25% +$2.18K ﹤0.01% 2088
2026
Q1 		$10.5K Sell
13,504
-1,735
-11% -$1.47K ﹤0.01% 3151
2025
Q4 		$11.9K Sell
15,239
-7,602
-33% -$6.24K ﹤0.01% 2776
2025
Q3 		$16.5K Sell
22,841
-346,286
-94% -$1.57M ﹤0.01% 2501
2025
Q2 		$1.87M Sell
369,127
-289,203
-44% -$1.14M 0.01% 503
2025
Q1 		$1.99M Buy
658,330
+658,115
+306,100% +$2.4M 0.02% 479
2024
Q4 		$779 Buy
+215
New +$651 ﹤0.01% 3242

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MAI Capital Management's ATYR Position: Q2 2026 in Review

MAI Capital Management increased its aTyr Pharma (ATYR) stake by 25% in Q2 2026, buying an estimated $2.18K and bringing the position to 16,846 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2088.

MAI Capital Management first reported a position in ATYR in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.99M in Q1 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • MAI Capital Management held 16,846 shares of aTyr Pharma worth $10.1K as of Q2 2026.
  • MAI Capital Management bought 3,342 aTyr Pharma shares in Q2 2026, an estimated $2.18K.
  • aTyr Pharma made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #2088 holding.
  • MAI Capital Management first reported a position in aTyr Pharma in Q4 2024 and has held it in 7 quarters since.
  • MAI Capital Management's aTyr Pharma position peaked at $1.99M in Q1 2025.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.